Onyx Biotec Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Onyx Biotec Ltd is ₹ 33 as of 30 Apr 15:30 . The P/E Ratio of Onyx Biotec Ltd is 0 as of March 2024 .The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 . The Market Cap of Onyx Biotec Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 . The Dividend Payout of Onyx Biotec Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh.
Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre. Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010.
Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Onyx Biotec Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Onyx Biotec Ltd or Remus Pharmaceuticals Ltd?

Market cap of Onyx Biotec Ltd is 59 Cr while Market cap of Remus Pharmaceuticals Ltd is 807 Cr

What are the key factors driving the stock performance of Onyx Biotec Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Onyx Biotec Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Onyx Biotec Ltd and Remus Pharmaceuticals Ltd?

As of May 4, 2026, the Onyx Biotec Ltd stock price is INR ₹33.0. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹685.3.

How do dividend payouts of Onyx Biotec Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Onyx Biotec Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.